PTC Therapeutics (PTCT) Is Weak On High Volume Today
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
Trade-Ideas LLC identified
(
) as a weak on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified PTC Therapeutics as such a stock due to the following factors:
- PTCT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $48.4 million.
- PTCT has traded 55,951 shares today.
- PTCT is trading at 2.29 times the normal volume for the stock at this time of day.
- PTCT is trading at a new low 4.01% below yesterday's close.
'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in PTCT with the Ticky from Trade-Ideas. See the FREE profile for PTCT NOW at Trade-Ideas
More details on PTCT:
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. Currently there are 7 analysts that rate PTC Therapeutics a buy, no analysts rate it a sell, and 2 rate it a hold.
The average volume for PTC Therapeutics has been 527,400 shares per day over the past 30 days. PTC has a market cap of $2.3 billion and is part of the health care sector and drugs industry. Shares are up 27.5% year-to-date as of the close of trading on Tuesday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates PTC Therapeutics as a
. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income.
Highlights from the ratings report include:
- PTC THERAPEUTICS INC's earnings per share declined by 12.0% in the most recent quarter compared to the same quarter a year ago. Earnings per share have declined over the last year. We anticipate that this should continue in the coming year. During the past fiscal year, PTC THERAPEUTICS INC reported poor results of -$3.21 versus -$1.56 in the prior year. For the next year, the market is expecting a contraction of 64.8% in earnings (-$5.29 versus -$3.21).
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 52.5% when compared to the same quarter one year ago, falling from -$17.89 million to -$27.27 million.
- Compared to other companies in the Biotechnology industry and the overall market, PTC THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- Net operating cash flow has increased to -$7.99 million or 44.73% when compared to the same quarter last year. Despite an increase in cash flow, PTC THERAPEUTICS INC's average is still marginally south of the industry average growth rate of 49.09%.
- Compared to its closing price of one year ago, PTCT's share price has jumped by 119.08%, exceeding the performance of the broader market during that same time frame. Regarding the future course of this stock, we feel that the risks involved in investing in PTCT do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.
- You can view the full PTC Therapeutics Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
null